HCYT
H-CYTE, Inc.
1W: +0.5%
1M: -60.0%
3M: -41.2%
1Y: -95.0%
3Y: -98.7%
5Y: -99.8%
$0.99
Last traded 2023-07-07 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.6M
52W Range0.5002-7.0
Volume325
Avg Volume1,523
Beta0.52
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael W. Yurkowsky
Employees2
SectorHealthcare
IndustryBiotechnology
IPO Date2014-12-19
Websitehcyte.com
2202 North West Shore Boulevard
Tampa, FL 33607
US
Tampa, FL 33607
US
888 664 2983
About H-CYTE, Inc.
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| WAGNER TODD R | C-Conversion | 303,107,000 | — | 2024-01-16 |
| WAGNER TODD R | C-Conversion | 303,107 | — | 2024-01-16 |
| FARRIOR J REX III | C-Conversion | 13,168,000 | — | 2024-01-16 |
| FARRIOR J REX III | C-Conversion | 13,168 | — | 2024-01-16 |
| Lynch Frederick J | X-InTheMoney | 8,321,785 | $0.01 | 2022-03-21 |